Background and Purpose: Fibromuscular dysplasia (FMD) is a non-atherosclerotic arteriopathy most often affecting the carotid and renal arteries. In the United States Registry for FMD, 41.7% of patients experienced an aneurysm and/or dissection by the time of entry into the Registry. We sought to determine the occurrence of neurovascular events after FMD diagnosis and any changes on cervical artery imaging that may be attributable to FMD. Methods: Patients followed at the Mount Sinai Medical Center (US Registry for FMD enrollment center) with confirmed FMD and > 1 cervical artery imaging study (at least ± 6 months from the baseline carotid duplex ultrasound [CDU]) between the years 2003 and 2015 were included. Medical records and cervical artery imaging ([CDU], magnetic resonance angiogram [MRA], and computed tomography angiogram [CTA]) were reviewed. New arterial dissection, aneurysm, transient ischemic attack, stroke, or new FMD findings were recorded. Results: Among 146 FMD patients with complete information, 52 (35.6%) had an aneurysm and 52 (35.6%) had a dissection. Mean clinical follow-up was 35.3 ± 25.3 months (range 5–153 months); patients underwent 4 ± 2.7 CDU (range 1–17); 86.3% had ≥1 neck MRA or CTA. After FMD diagnosis, 3 patients (2%) experienced a new carotid artery dissection; 1 patient experienced a stroke due to concomitant atherosclerosis. No new aneurysms occurred. In patients with cervical artery FMD, imaging findings remained stable throughout follow-up. No patient developed new cervical artery FMD findings on follow-up imaging. Conclusions: No new cervical artery FMD or aneurysm was observed on subsequent imaging. New carotid dissection was uncommon over a mean follow-up period of 35.3 ± 25.3 months and was the only non-atherosclerotic vascular event observed after FMD diagnosis.

Keywords:
Fibromuscular dysplasia, Carotid artery, Internal, Dissection, Natural history, Stroke
1.
Slovut DP, Olin JW: Fibromuscular dysplasia. N Engl J Med 2004; 350: 1862–1871.
2.
Olin JW, Sealove BA: Diagnosis, management, and future developments of fibromuscular dysplasia. J Vasc Surg 2011; 53: 826–36.e1.
3.
Savard S, Steichen O, Azarine A, Azizi M, Jeunemaitre X, Plouin PF: Association between 2 angiographic subtypes of renal artery fibromuscular dysplasia and clinical characteristics. Circulation 2012; 126: 3062–3069.
4.
Olin JW: Is fibromuscular dysplasia a single disease? Circulation 2012; 126: 2925–2927.
5.
Kadian-Dodov D, Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi YW, et al: Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U.S. registry for FMD. J Am Coll Cardiol 2016; 68: 176–185.
6.
Sethi SS, Lau JF, Godbold J, Gustavson S, Olin JW: The S curve: a novel morphological finding in the internal carotid artery in patients with fibromuscular dysplasia. Vasc Med 2014; 19: 356–362.
7.
Persu A, Touze E, Mousseaux E, Barral X, Joffre F, Plouin PF: Diagnosis and management of fibromuscular dysplasia: an expert consensus. Eur J Clin Invest 2012; 42: 338–347.
8.
Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, et al: The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 2012; 125: 3182–3190.
9.
Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, et al: Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation 2014; 129: 1048–1078.
10.
Schievink WI: Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med 2001; 344: 898–906.
11.
Dziewas R, Konrad C, Drager B, Evers S, Besselmann M, Ludemann P, et al: Cervical artery dissection–clinical features, risk factors, therapy and outcome in 126 patients. J Neurol 2003; 250: 1179–1184.
12.
Bejot Y, Aboa-Eboule C, Debette S, Pezzini A, Tatlisumak T, Engelter S, et al: Characteristics and outcomes of patients with multiple cervical artery dissection. Stroke 2014; 45: 37–41.
13.
Schievink WI, Mokri B, O’Fallon WM: Recurrent spontaneous cervical-artery dissection. N Engl J Med 1994; 330: 393–397.
14.
Pasquini M, Trystram D, Nokam G, Gobin-Metteil MP, Oppenheim C, Touze E: Fibromuscular dysplasia of cervicocephalic arteries: prevalence of multisite involvement and prognosis. Rev Neurol (Paris) 2015; 171: 616–623.
15.
Corrin LS, Sandok BA, Houser OW: Cerebral ischemic events in patients with carotid artery fibromuscular dysplasia. Arch Neurol 1981; 38: 616–618.
16.
Stewart MT, Moritz MW, Smith RB 3rd, Fulenwider JT, Perdue GD: The natural history of carotid fibromuscular dysplasia. J Vasc Surg 1986; 3: 305–310.
17.
Wells RP, Smith RR: Fibromuscular dysplasia of the internal carotid artery: a long term follow-up. Neurosurgery 1982; 10: 39–43.
18.
Neumyer M, Thiele B, Weidner W: Prosepctive validation of prescreening with duplex scanning in symptomatic patients with cerebrovascular disease. J Vasc Technology 1987; 11: 29–32.
19.
Olin JW, Fonseca C, Childs MB, Piedmonte MR, Hertzer NR, Young JR: The natural history of asymptomatic moderate internal carotid artery stenosis by duplex ultrasound. Vasc Med 1998; 3: 101–108.
20.
Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al: Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 2012; 34: 290–296.
21.
Narula N, Kadian-Dodov D, Olin JW: Fibromuscular dysplasia: contemporary concepts and future directions. Prog Cardiovasc Dis 2018; 60: 580–585.
22.
Lather HD, Gornik HL, Olin JW, Gu X, Heidt ST, Kim ESH, et al: Prevalence of intracranial aneurysm in women with fibromuscular dysplasia: a report from the US registry for fibromuscular dysplasia. JAMA Neurol 2017; 74: 1081–1087.
23.
Olin JW, Kadian-Dodov D: Fibromuscular dysplasia: looking beyond the “String of Beads”. JACC Cardiovasc Imaging 2017; 10: 562–564.
24.
Bolen MA, Brinza E, Renapurkar RD, Kim ESH, Gornik HL: Screening CT angiography of the aorta, visceral branch vessels, and pelvic arteries in fibromuscular dysplasia. JACC Cardiovasc Imaging 2017; 10: 554–561.
25.
Plouin PF, Baguet JP, Thony F, Ormezzano O, Azarine A, Silhol F, et al: High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: the ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia). Hypertension 2017; 70: 652–658.
26.
Olin JW: Expanding clinical phenotype of fibromuscular dysplasia. Hypertension 2017; 70: 488–489.
27.
Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al: 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. Stroke 2011; 42:e420–e463.
28.
Persu A, Giavarini A, Touze E, Januszewicz A, Sapoval M, Azizi M, et al: European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014; 32: 1367–1378.
29.
de Bray JM, Marc G, Pautot V, Vielle B, Pasco A, Lhoste P, et al: Fibromuscular dysplasia may herald symptomatic recurrence of cervical artery dissection. Cerebrovasc Dis 2007; 23: 448–452.
30.
Bejot Y, Daubail B, Debette S, Durier J, Giroud M: Incidence and outcome of cerebrovascular events related to cervical artery dissection: the Dijon Stroke Registry. Int J Stroke 2014; 9: 879–882.
31.
Debette S, Grond-Ginsbach C, Bodenant M, Kloss M, Engelter S, Metso T, et al: Differential features of carotid and vertebral artery dissections: the CADISP study. Neurology 2011; 77: 1174–1181.
32.
Debette S, Kamatani Y, Metso TM, Kloss M, Chauhan G, Engelter ST, et al: Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection. Nat Genet 2015; 47: 78–83.
33.
Kiando SR, Tucker NR, Castro-Vega LJ, Katz A, D’Escamard V, Treard C, et al: PHACTR1 is a genetic susceptibility locus for fibromuscular dysplasia supporting its complex genetic pattern of inheritance. PLoS Genet 2016; 12:e1006367.
34.
Osborn AG, Anderson RE: Angiographic spectrum of cervical and intracranial fibromuscular dysplasia. Stroke 1977; 8: 617–626.
35.
Harriott AM, Zimmerman E, Singhal AB, Jaff MR, Lindsay ME, Rordorf GA: Cerebrovascular fibromuscular dysplasia: the MGH cohort and literature review. Neurol Clin Pract 2017; 7: 225–236.
36.
European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, et al: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.
37.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(suppl 2):S1–S45.
38.
So EL, Toole JF, Dalal P, Moody DM: Cephalic fibromuscular dysplasia in 32 patients: clinical findings and radiologic features. Arch Neurol 1981; 38: 619–622.
39.
Effeney DJ, Krupski WC, Stoney RJ, Ehrenfeld WK: Fibromuscular dysplasia of the carotid artery. Aust N Z J Surg 1983; 53: 527–531.
40.
Chiche L, Bahnini A, Koskas F, Kieffer E: Occlusive fibromuscular disease of arteries supplying the brain: results of surgical treatment. Ann Vasc Surg 1997; 11: 496–504.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.